PRIMARY HYPERHOMOCYSTENEMIA AS A RISK FACTOR OF ASSOCIATED DEVELOPMENT OF CEREBROVASCULAR, RENAL AND ONCOLOGICAL PATHOLOGY


Cite item

Full Text

Abstract

The major disorders of patients with primary hyperhomocysteinemia are presented in the article. The pathogenetic mechanisms of cerebrovascular, renal and oncological pathology in patients with hyperhomocysteinemia are given (based on a clinical case). The possible mechanisms and correction of cardiovascular events, chronic kidney disease and oncogenesis in patients with primary hyperhomocysteinemia are discussed in detail.

About the authors

Alexey E Khrulev

Nizhny Novgorod State Medical Academy

Email: alexey_khrulev@mail.ru
кафедра неврологии, нейрохирургии и медицинской генетики 603005, Nizhny Novgorod, Minin and Pozharsky Square, 10/1

Vera N Grigoryeva

Nizhny Novgorod State Medical Academy

кафедра неврологии, нейрохирургии и медицинской генетики 603005, Nizhny Novgorod, Minin and Pozharsky Square, 10/1

Mariya A Emelyanova

Nizhny Novgorod State Medical Academy

кафедра неврологии, нейрохирургии и медицинской генетики 603005, Nizhny Novgorod, Minin and Pozharsky Square, 10/1

Sergey E Khrulev

Privolzhsky Federal Medical Research Center of Ministry of Public Health

603155, Nizhny Novgorod, Verkhnevolzhskaya Nab., 18

References

  1. Гайфуллина Р.Ф., Катина М.Н., Ризванова Ф.Ф. Роль генетического полиморфизма в патогенезе цереброваскулярных заболеваний // Казанский медицинский журнал. 2012. № 4. С. 663-667.
  2. Ефимов В.С., Озолиня Л.А., Кашежева А.З. и др. Гипергомоцистеинемия в клинической практике: руководство. М.: ГЭОТАР-Медиа, 2013. 80 с.
  3. Калашникова Л.А., Добрынина Л.А., Устюжанина М.К. Гипергомоцистеинемия и поражение головного мозга // Неврологический журнал. 2004. №3. С. 48-54.
  4. Нестеренко О.В., Бородулин В.Б., Горемыкин В.И. и др. Значение гипергомоцистеинемии (ГГЦ) в патогенезе хронического пиелонефрита // Фундаментальные исследования. 2014. № 7-1. С. 193-196.
  5. Павленко О.А., Колосовская О.Ф., Сибирева Е.Ю. и др. Распространенность, клиническое и прогностическое значение полиморфизма генов II, V факторов свертывания крови и метилентетрагидрофолатредуктазы у пациентов с хронической болезнью почек // Бюллетень сибирской медицины. 2009. № 4 (2). С. 80-85.
  6. Смирнов А.В., Добронравов В.А., Каюков И.Г. Проблема хронической болезни почек в современной медицине // Артериальная гипертензия. 2006. №3 (12). C. 185-193.
  7. Akbulut S., Altiparmak E. Increased levels of homocysteine in patients with ulcerative colitis // World J Gastroenterol. 2010. Vol. 16, №19. P. 2411-2416.
  8. Bezemerl D., Doggen C.J. et al. No association between the common MTHFR 677 C >T polymorphism and venous thrombosis: results from the MEGA study // Arch. Intern. Med. 2007. Vol. 96, №167. P. 497-501.
  9. Botto L., Yang D.Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review // Am. J. Epidemiol. 2000. Vol. 151. P. 862-877.
  10. Boushey С.J., Beresford S.A., Omenn G.S. et al. Quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes // J. A. M. A. 1995. Vol. 274. P. 1777-1782.
  11. Castro R., Rivera I., Ravasco P. et al. 5,10-Methylenetetra-hydrofolate reductase (MTHFR) 677C-T and 1298A-C mutations are associated with DNA hypomethylation // J. Med. Genet. 2004. Vol.41. P. 454-458.
  12. Clarke R., Daly L., Robinson K. et al. Hyperhomocysteinemia: an independent risk factor for vascular disease // N. Engl. J. Med. 1991. Vol. 324. P. 1149-1155.
  13. Cohen V., Panet-Raymond V., Sabbaghian N. et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy // Clin Cancer Res. 2003. Vol. 9(5). P. 1611-1616.
  14. Gershoni-Baruch R., Dagan E., Israeli D. et al.Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women // Eur J Cancer. 2000. Vol. 36(18). P. 2313-2319.
  15. Giovannucci E., Chen J., Smith-Warner S.A. et al. Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas // Cancer Epidemiol Biomarkers Prev. 2003. Vol. 12. P. 970-975.
  16. Sucker C. et al. The TT genotype of the C677T polymorphism in the methylentetrahydrofolate reductase as a risk factor in thrombotic microangiopathies: results from a pilot study // Clin Appl Thromb Hemost. 2009. Vol.15, №3. P. 283-288.
  17. Stuppia L., Gatta V., Scarciolla O. et al. The methylenetethra-hydrofolate reductase (MTHFR) C677T polymorphism and male infertility in Italy // Endocrinol. Invest. 2003. Vol. 26, №7. P. 620-622.

Copyright (c) 2017 Khrulev A.E., Grigoryeva V.N., Emelyanova M.A., Khrulev S.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies